ArticleMediterranean journal of rheumatology2025
Prevalence of Anti-Synthetase Syndrome in Patients of Interstitial Lung Disease with Connective Tissue Diseases and Autoimmune Features: A Cross-Sectional Study.
Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in Biomarkers and Therapeutic Targets for Idiopathic Inflammatory Myopathies Related Lung Disease.Clinical reviews in allergy & immunology · 2026Review
- Reclassification of Seronegative Rheumatoid Arthritis as Anti-PL-12 Antisynthetase Syndrome with Interstitial Lung Disease and Joint Involvement-Case Report.Reports (MDPI) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Anti-synthetase syndrome (ASS) is a rare autoimmune disease with heterogenous manifestations. Interstitial lung disease (ILD) is one among its common manifestations. The aim of this study was to evaluate the prevalence of ASS in cases of ILD associated with autoimmune features and describe the clinical, serological, and radiological profile in them. Methods: This cross-sectional study included a total of 100 patients: 50 cases each of connective tissue disease-related ILD (CTD-ILD) and interstitial pneumonia with autoimmune features (IPAF). Results: Four cases of CTD-ILD and 7 cases of IPAF had anti-ARS auto-antibodies. All eleven of them fulfilled Connor's criteria for ASS. The classic triad of arthritis, myositis, and ILD was present only in two cases. Anti-nuclear antibody (ANA) was positive in 63.6%. Anti-Jo1 (54.56%), Anti-PL12(27.3%), anti-PL7(18.2%), and anti-EJ(18.2%) were the anti ARS autoantibodies. Though generally considered to be mutually exclusive, anti-PL12 and anti-EJ antibodies were found together in two cases. Myalgia was associated with all four ARS antibodies. Anti-Jo1 antibody was associated with Raynaud's phenomenon, polyarthralgia, polyarthritis, and myopathy. Anti-PL7 antibody was associated with myopathy and mechanic's hands. Anti-PL12 and anti-EJ antibodies were associated with inflammatory poly-arthritis, polyarthralgia, and unexplained fever. Non-specific interstitial pneumonia (NSIP) was the most common radiologic pattern of ILD (81.8%). The remaining two had Usual interstitial pneumonia (UIP) pattern and were positive for anti-Jo1 antibody. Conclusion: ASS can present in many ways, often incomplete at the onset without the classic clinical triad. Anti-ARS autoantibodies can be found in established CTDs. Anti-cytoplasmic antibodies (not ANA) must be used to screen for ASS in suspected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.